Navigation Links
Watson CFO Mark W. Durand to Take Leave of Absence
Date:7/27/2009

MORRISTOWN, N.J., July 27 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced that effective today Mark W. Durand, Senior Vice President and Chief Financial Officer, has taken a leave of absence from the Company for health reasons. Paul Bisaro, President and Chief Executive Officer of Watson, announced that R. Todd Joyce, Vice President, Corporate Controller and Treasurer, will serve as Acting Principal Financial Officer, effective immediately.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., (NYSE: WPI) is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical).

For press releases and other company information, visit the Watson website at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Florida Hospital ... a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up life-threatening blood ... the Pepin Family Foundation. , “We greatly appreciate this gift from Constellation Brands. ...
(Date:2/19/2017)... , ... February 19, 2017 , ... ... for connected home healthcare, will join forces with Healthwise ® at ... Healthwise, the industry leader in evidence-based health education, technology and services, will ...
(Date:2/18/2017)... , ... February 17, 2017 , ... Park Cities Pet ... Behave” Show on the Pet Life Radio network. The episode, which was posted ... of topics including: what factors led to Park Cities Pet Sitter’s being awarded the ...
(Date:2/17/2017)... San Diego, CA (PRWEB) , ... February 17, ... ... new initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively ... Counties. , “The Board of Trustees has long considered it our duty to ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... February 17, ... ... Devices, Implementing the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. ... , Do manufacturers distinguish between corrective action (CA) and preventive action ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... Feb. 19, 2017   AC Group Inc. , ... ranking of vendors in the PMS/EHR healthcare marketplace, will ... system requirements to succeed in this ecosystem at HIMSS,17. ... together information obtained from over 200 ACOs, compared and ... and services companies that are providing different pieces of ...
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 /PRNewswire/ ... announced that positive Phase 1 clinical data for Nektar,s ... carcinoma (RCC) were presented at ASCO GU 2017.  NKTR-214 ... cancer-fighting T cells and Natural Killer (NK) cell abundance ... PD-1 on these immune cells.  The results were presented ...
(Date:2/18/2017)... , Feb. 17, 2017  Pharmaceutical companies have long ... products either in development or already on the market.   ... the pharma industry to alter how it manages advisory board ... leader Best Practices, LLC conducted a new study focused on ... ...
Breaking Medicine Technology: